Mortality of lung cancer as a second primary malignancy: A population-based cohort study.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Loo, Billy W
MetadataShow full item record
CitationMortality of lung cancer as a second primary malignancy: A population-based cohort study. 2109, 8(6):3269-3277 Cancer Med
AbstractLung cancer as a second primary malignancy (lung-2) is increasingly common, but its prognosis is poorly understood. This study aims to examine the overall and cancer-specific survival of patients diagnosed with lung-2 compared to lung-1. Primary lung cancer patients diagnosed from 1988 to 2014 in the Surveillance, Epidemiology, and End Results (SEER) program were included. Lung-2 was identified in patients with a previous diagnosis of nonlung primary malignancy in SEER. Hazard ratios (HRs) of overall and lung cancer-specific mortality were estimated among patients with lung-2 compared to lung-1, adjusting for age and calendar period at diagnosis, sex, race, socioeconomic status, tumor stage, histology, tumor grade, and treatment. A total of 679 541 and 85 758 patients were identified as lung-1 and lung-2, respectively. Compared to lung-1, patients with lung-2 were more likely to be diagnosed at localized stage, with smaller primary tumor, and treated with surgery. Lung-2 patients were at lower risk of lung cancer-specific mortality in the first 5 years (HR, 0.77; 95% CI, 0.76-0.78 at <1 year; HR, 0.87; 95% CI, 0.86-0.89 from 1 to <5 years) but at higher risk thereafter (HR, 1.32; 95% CI, 1.27-1.37 from 5 to 10 years), independent of tumor characteristics and cancer treatment. Similar pattern was found for overall mortality, although the survival benefit was restricted to the first year after diagnosis. Patients diagnosed with lung-2 face a favorable lung cancer-specific survival within the early period after diagnosis. A conservative approach to manage lung-2 solely based on malignancy history is not supported.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
- Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
- Authors: Wang C, Hu K, Deng L, He W, Fang F, Tamimi RM, Lu D
- Issue date: 2021 May 3
- The prognostic significance of the 8th edition AJCC TNM staging system for non-small-cell lung cancer is not applicable to lung cancer as a second primary malignancy.
- Authors: Shi S, Xie H, Yin W, Zhang Y, Peng X, Yu F, Shemanski KA, Kim AW, Wang X
- Issue date: 2020 Jun
- Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
- Authors: Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE
- Issue date: 2016 Aug
- Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients.
- Authors: Milano MT, Li H, Constine LS, Travis LB
- Issue date: 2011 Dec 15
- Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
- Authors: Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K
- Issue date: 2016 Oct